Understanding how Wnt5a signaling affects bone growth and disorders
Mechanism of Wnt5a signaling in skeletal development and diseases
This study is looking at how a protein called Wnt5a affects bone growth and development, especially in people with conditions like Robinow syndrome, which can cause dwarfism and other bone issues, to find new ways to help treat these problems.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Alabama at Birmingham NIH-funded |
| Lab location | 1 site (Birmingham, United States) |
| Project ID | NIH-10833687 on NIH RePORTER |
What this research studies
This research investigates the role of Wnt5a signaling in the development of the skeletal system and its implications for congenital skeletal disorders. By studying genetic mutations in humans and mice, the project aims to uncover how Wnt5a influences limb development and how alterations in its signaling can lead to conditions like Autosomal Dominant Robinow syndrome, which causes dwarfism and skeletal dysplasia. The researchers will explore different isoforms of Wnt5a and their effects on signaling pathways that are crucial for proper skeletal formation. This work could lead to new strategies for treating skeletal disorders and enhancing bone regeneration.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals with congenital skeletal disorders, particularly those with mutations in the WNT5A gene.
Not a fit: Patients with skeletal disorders not related to WNT5A mutations may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatments for congenital skeletal disorders and better strategies for bone regeneration.
How similar studies have performed: Previous studies have shown promising results in understanding Wnt signaling pathways, indicating that this approach has potential for success.
Where this research is happening
Birmingham, United States
- University of Alabama at Birmingham — Birmingham, United States (Active)
Researchers
- Principal investigator: Wang, Jianbo — University of Alabama at Birmingham
- Study coordinator: Wang, Jianbo
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.